{"groups":[{"description":"RP6530 administered 200 mg orally twice a day.","id":"FG000","title":"Dose escalation_Cohort 1_200 mg"},{"description":"RP6530 administered 400 mg orally twice a day.","id":"FG001","title":"Dose escalation_Cohort 2_400 mg"},{"description":"RP6530 administered 800 mg orally twice a day under fasting condition","id":"FG002","title":"Dose escalation_Cohort 3_800 mg (Fasting)"},{"description":"RP6530 administered 800 mg orally twice a day under fed condition","id":"FG003","title":"Dose escalation_Cohort 4_800 mg (Fed)"},{"description":"RP6530 administered 800 mg orally twice a day under fasting condition","id":"FG004","title":"Dose expansion_PTCL_800 mg (Fasting)"},{"description":"RP6530 administered 800 mg orally twice a day under fasting condition","id":"FG005","title":"Dose expansion_CTCL_800 mg (Fasting)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Premature discontinuation due to PD"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"19"},{"groupId":"FG005","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"19"},{"groupId":"FG005","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}